Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC

Launched by ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL · Feb 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for patients with anaplastic thyroid carcinoma (ATC), a type of aggressive cancer affecting the thyroid gland. Researchers want to see how safe and tolerable it is to combine a special type of immune cell, called CAR-NK cells, with a medication known as a PD-1 monoclonal antibody. The goal is to determine if this combination can help fight the cancer effectively.

To participate in this trial, individuals must be between 18 and 75 years old, have a confirmed diagnosis of ATC with a tumor that is at least 1 cm in size, and have good liver and kidney function. They should also be able to commit to the treatment and follow-up visits. Unfortunately, those who are pregnant or breastfeeding, have certain immune system or blood disorders, or other serious health issues may not be eligible. Participants can expect to receive close monitoring by healthcare professionals throughout the trial to ensure their safety and to gather information about how well the treatment works.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18-75 years (including boundary values), male or female.
• • 2. Be diagnosed with anaplastic thyroid cancer histopathologically with a measurable lesion≥1cm.
• • 3. Liver and kidney function is good, and can tolerate treatment.
• • 4. Be able to cooperate with the completion of treatment and follow-up work.
• • 5. No other systemic diseases, including other malignancies.
• Exclusion Criteria:
• • 1. Need to breastfeed the baby or have fertility needs；
• • 2. Immune system diseases;
• • 3. Diseases of the blood system;
• • 4. Mental system diseases;
• • 5. Interstitial pneumonia, lung disease, etc.;
• • 6. Failure to follow rules of this study.